Innate Pharma to Attend June 2024 Investor Conferences

Innate Pharma SA, a biotechnology company listed on Euronext Paris and Nasdaq, recently disclosed the participation of its executive team in several upcoming conferences. These events are significant for the company as they showcase its involvement in the global healthcare landscape and offer an opportunity to discuss advancements in cancer immunotherapies.

The company's CEO, Hervé Brailly, along with Executive Vice President and Chief Medical Officer Sonia Quaratino, EVP and Chief Operating Officer Yannis Morel, and EVP and President of US Operations Arvind Sood, are scheduled to represent Innate Pharma at four notable conferences in June 2024. These engagements include:

1. Jefferies Global Healthcare Conference: Taking place in New York, United States, from June 5-6, 2024, this event will bring together a diverse range of stakeholders from the healthcare industry.

2. Goldman Sachs 45th Annual Global Healthcare Conference: Scheduled for June 10-13, 2024, in Miami, United States, this conference is an important platform for discussing healthcare innovations and investment opportunities.

3. H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference: This virtual event on June 25, 2024, focuses on the latest developments in immune cell engager technologies, a key area of interest for Innate Pharma.

4. Stifel 2nd European Healthcare Summit: Held in Lyon, France, from June 25-27, 2024, this summit will gather European healthcare leaders to discuss regional and global healthcare trends.

Innate Pharma is dedicated to developing immunotherapies for cancer treatment, leveraging its proprietary ANKET® (Antibody-based NK cell Engager Therapeutics) platform. The company’s portfolio includes several promising programs. Lacutamab, for example, addresses advanced forms of cutaneous T cell lymphomas and peripheral T cell lymphomas. Monalizumab, developed in collaboration with AstraZeneca, targets non-small cell lung cancer. Additionally, Innate Pharma is advancing ANKET® multi-specific NK cell engagers to tackle various tumor types.

The company’s partnerships with major biopharmaceutical entities such as Sanofi and AstraZeneca, as well as leading research institutions, facilitate accelerated innovation in cancer research and therapeutic development. Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma continues to make strides in the biopharmaceutical sector.

Innate Pharma's shares are traded under the ticker codes IPH on Euronext Paris and IPHA on Nasdaq. The company’s ISIN code is FR0010331421, and its LEI is 9695002Y8420ZB8HJE29.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!